Schedule a Meeting

Calls from potential investors, contract negotiations with major health care systems and tweet-outs from White House staff are just a few of the things occupying Coralville-based IDx LLC these days.

With a product that could change the way that health care is delivered, IDx is in an enviable position.

“We may be the most talked-about privately held technology company in the state of Iowa,” said Gary Seamans, chairman and CEO.

In April, IDx received first-ever approval from the U.S. Food and Drug Administration for an autonomous device that uses artificial intelligence to diagnose diabetic retinopathy, a diabetes complication that can cause blindness without early detection and treatment.

In June, the University of Iowa Hospitals and Clinics became the first health care provider to employ the new technology, called LumineticsCore™ (formerly known as IDx-DR).

Because it does not require a physician to interpret the results, LumineticsCore (formerly known as IDx-DR) represents an exciting advancement in the field of health care, opening the doors to other technology that could improve the accessibility and affordability of health care.

It’s also helped put Iowa on the map along with such technology hubs as Silicon Valley, Research Triangle in North Carolina and Boston, Seamans said.